Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) saw a significant decrease in short interest in February. As of February 27th, there was short interest totaling 150,744 shares, a decrease of 65.5% from the February 12th total of 436,863 shares. Based on an average trading volume of 184,747 shares, the days-to-cover ratio is presently 0.8 days. Approximately 1.4% of the company’s shares are short sold. Approximately 1.4% of the company’s shares are short sold. Based on an average trading volume of 184,747 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Trading of Biofrontera

A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in shares of Biofrontera by 54.2% during the fourth quarter. Geode Capital Management LLC now owns 65,677 shares of the company’s stock worth $37,000 after buying an additional 23,074 shares during the period. Rosalind Advisors Inc. raised its position in Biofrontera by 51.5% in the 2nd quarter. Rosalind Advisors Inc. now owns 976,448 shares of the company’s stock valued at $695,000 after buying an additional 332,055 shares during the last quarter. Finally, AIGH Capital Management LLC raised its position in Biofrontera by 7.3% in the 3rd quarter. AIGH Capital Management LLC now owns 1,046,050 shares of the company’s stock valued at $1,030,000 after buying an additional 71,525 shares during the last quarter. 10.08% of the stock is currently owned by institutional investors.

Biofrontera Trading Up 0.7%

BFRI opened at $0.83 on Wednesday. The stock has a market capitalization of $9.67 million, a P/E ratio of -0.51 and a beta of 0.61. Biofrontera has a 12 month low of $0.54 and a 12 month high of $1.19. The firm’s fifty day simple moving average is $0.85 and its 200 day simple moving average is $0.88.

Analysts Set New Price Targets

Separately, Benchmark reiterated a “buy” rating on shares of Biofrontera in a report on Friday, November 14th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $2.75.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.